RJA
CCCC icon

Raymond James & Associates’s C4 Therapeutics CCCC Stock Holding History

Raymond James & Associates’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100,984
Closed -$571K – 3936
2023
Q4 		$571K Buy
100,984
+9,604
+11% +$21.9K ﹤0.01% 2874
2023
Q3 		$170K Buy
91,380
+7,146
+8% +$21.8K ﹤0.01% 3502
2023
Q2 		$232K Buy
84,234
+21,132
+33% +$67.9K ﹤0.01% 3402
2023
Q1 		$198K Buy
63,102
+545
+0.9% +$3.21K ﹤0.01% 3498
2022
Q4 		$369K Sell
62,557
-875
-1% -$7.25K ﹤0.01% 3086
2022
Q3 		$556K Buy
63,432
+34,390
+118% +$357K ﹤0.01% 2790
2022
Q2 		$219K Buy
+29,042
New +$256K ﹤0.01% 3443

Other funds holding CCCC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James & Associates's CCCC Position: Q1 2024 in Review

Raymond James & Associates sold out of C4 Therapeutics (CCCC) in Q1 2024, closing a stake of 100,984 shares — an estimated $571K sold.

Raymond James & Associates first reported a position in CCCC in Q2 2022 and held it in 7 quarters. The position peaked at $571K in Q4 2023. 106 funds tracked by Wall St. Rank hold CCCC as of Q1 2024.

  • Raymond James & Associates reported no remaining C4 Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Raymond James & Associates sold 100,984 C4 Therapeutics shares in Q1 2024, an estimated $571K.
  • Raymond James & Associates first reported a position in C4 Therapeutics in Q2 2022 and held it in 7 quarters.
  • Raymond James & Associates's C4 Therapeutics position peaked at $571K in Q4 2023.
  • 106 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2024.

Based on Raymond James & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.